Advanced Hematologic Malignancies clinical trials

Explore recruiting advanced hematologic malignancies clinical trials.

Recruiting advanced hematologic malignancies studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Hematologic Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

France, Germany, Spain, Poland, Italy, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants

Belgium, Sweden, Spain, France, Italy, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Hematologic Malignancies trials by city

Advanced Hematologic Malignancies clinical trials

Recruiting advanced hematologic malignancies studies right now

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies